Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery
Haiyan Fu, Marcela P Cataldi, Tierra A Ware, Kimberly Zaraspe, Aaron S Meadows, Darren A Murrey, Douglas M McCarty, Haiyan Fu, Marcela P Cataldi, Tierra A Ware, Kimberly Zaraspe, Aaron S Meadows, Darren A Murrey, Douglas M McCarty
Abstract
The reversibility of neuropathic lysosomal storage diseases, including MPS IIIA, is a major goal in therapeutic development, due to typically late diagnoses and a large population of untreated patients. We used self-complementary adeno-associated virus (scAAV) serotype 9 vector expressing human N-sulfoglucosamine sulfohydrolase (SGSH) to test the efficacy of treatment at later stages of the disease. We treated MPS IIIA mice at 1, 2, 3, 6, and 9 months of age with an intravenous injection of scAAV9-U1a-hSGSH vector, leading to restoration of SGSH activity and reduction of glycosaminoglycans (GAG) throughout the central nervous system (CNS) and somatic tissues at a dose of 5E12 vg/kg. Treatment up to 3 months age improved learning ability in the Morris water maze at 7.5 months, and lifespan was normalized. In mice treated at 6 months age, behavioral performance was impaired at 7.5 months, but did not decline further when retested at 12 months, and lifespan was increased, but not normalized. Treatment at 9 months did not increase life-span, though the GAG storage pathology in the CNS was improved. The study suggests that there is potential for gene therapy intervention in MPS IIIA at intermediate stages of the disease, and extends the clinical relevance of our systemic scAAV9-hSGSH gene delivery approach.
Figures
References
- Neufeld, EF, and Muenzer, J (2001). The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds.). The Metabolic & Molecular Basis of Inherited Disease. 8th edn. McGraw-Hill: New York; St Louis; San Francisco. pp. 3421–3452.
- Freeman, C and Hopwood, JJ (1986). Human liver sulphamate sulphohydrolase. Determinations of native protein and subunit Mr values and influence of substrate agylcone structure on catalytic properties. Biochem J 234: 83–92.
- Yogalingam, G and Hopwood, JJ (2001). Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat 18: 264–281.
- Valstar, MJ, Ruijter, GJ, van Diggelen, OP, Poorthuis, BJ and Wijburg, FA (2008). Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31: 240–252.
- Cleary, MA and Wraith, JE (1993). Management of mucopolysaccharidosis type III. Arch Dis Child 69: 403–406.
- Crawley, AC, Marshall, N, Beard, H, Hassiotis, S, Walsh, V, King, B et al. (2011). Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol Dis 43: 422–434.
- Hemsley, KM, Norman, EJ, Crawley, AC, Auclair, D, King, B, Fuller, M et al. (2009). Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs–a proof of principle study. Mol Genet Metab 98: 383–392.
- Mader, KM, Beard, H, King, BM and Hopwood, JJ (2008). Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes Brain Behav 7: 740–753.
- Lau, AA, Rozaklis, T, Ibanes, S, Luck, AJ, Beard, H, Hassiotis, S et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491: 53–57.
- Sergijenko, A, Langford-Smith, A, Liao, AY, Pickford, CE, McDermott, J, Nowinski, G et al. (2013). Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 21: 1938–1949.
- Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59–65.
- Duque, S, Joussemet, B, Riviere, C, Marais, T, Dubreil, L, Douar, AM et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17: 1187–1196.
- Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073–1080.
- Ruzo, A, Marcó, S, García, M, Villacampa, P, Ribera, A, Ayuso, E et al. (2012). Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 23: 1237–1246.
- Osborn, MJ, McElmurry, RT, Peacock, B, Tolar, J and Blazar, BR (2008). Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther 16: 1459–1466.
- Scott, HS, Blanch, L, Guo, XH, Freeman, C, Orsborn, A, Baker, E et al. (1995). Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 11: 465–467.
- McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P and Samulski, RJ (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112–2118.
- McCarty, DM, Monahan, PE and Samulski, RJ (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8: 1248–1254.
- Bartlett, JS, Sethna, M, Ramamurthy, L, Gowen, SA, Samulski, RJ, and Marzluff, WF (1996). Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci USA 93: 8852–8857.
- Ashworth, JL, Biswas, S, Wraith, E and Lloyd, IC (2006). Mucopolysaccharidoses and the eye. Surv Ophthalmol 51: 1–17.
- Heldermon, CD, Hennig, AK, Ohlemiller, KK, Ogilvie, JM, Herzog, ED, Breidenbach, A et al. (2007). Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2: e772.
- Summers, CG and Ashworth, JL (2011). Ocular manifestations as key features for diagnosing mucopolysaccharidoses. Rheumatology (Oxford) 50 Suppl 5: v34–v40.
- Bhaumik, M, Muller, VJ, Rozaklis, T, Johnson, L, Dobrenis, K, Bhattacharyya, R et al. (1999). A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9: 1389–1396.
- Warburton, EC, Baird, A, Morgan, A, Muir, JL and Aggleton, JP (2001). The conjoint importance of the hippocampus and anterior thalamic nuclei for allocentric spatial learning: evidence from a disconnection study in the rat. J Neurosci 21: 7323–7330.
- Karpova, EA, Voznyi YaV, Keulemans, JL, Hoogeveen, AT, Winchester, B, Tsvetkova, IV et al. (1996). A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J Inherit Metab Dis 19: 278–285.
- van de Lest, CH, Versteeg, EM, Veerkamp, JH and van Kuppevelt, TH (1994). Quantification and characterization of glycosaminoglycans at the nanogram level by a combined azure A-silver staining in agarose gels. Anal Biochem 221: 356–361.
- Fu, H, Kang, L, Jennings, JS, Moy, SS, Perez, A, Dirosario, J et al. (2007). Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 14: 1065–1077.
- de Jong, JG, Wevers, RA, Laarakkers, C and Poorthuis, BJ (1989). Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 35: 1472–1477.
Source: PubMed